牛牛AI助理已提取核心訊息
AbbVie Inc. officer Perry C Siatias is set to sell 9,911 common shares of the company on February 29, 2024, according to a recent filing. The shares, valued at an aggregate market value of $1,756,912.07, were acquired as performance shares directly from the issuer on February 28, 2024. This transaction follows a recent history of sales by Siatias over the past three months, totaling 16,672 shares for gross proceeds of $2,937,556.66. The planned sale is part of a trading plan adopted on November 1, 2023.
AbbVie Inc. officer Perry C Siatias is set to sell 9,911 common shares of the company on February 29, 2024, according to a recent filing. The shares, valued at an aggregate market value of $1,756,912.07, were acquired as performance shares directly from the issuer on February 28, 2024. This transaction follows a recent history of sales by Siatias over the past three months, totaling 16,672 shares for gross proceeds of $2,937,556.66. The planned sale is part of a trading plan adopted on November 1, 2023.
根據最近的一份文件，艾伯維公司高管佩裏·西亞蒂亞斯定於2024年2月29日出售該公司的9,911股普通股。這些股票的總市值爲1,756,912.07美元，於2024年2月28日作爲績效股票直接從發行人手中收購。該交易遵循了西亞蒂亞斯在過去三個月中的近期銷售記錄，共計16,672股股票，總收益爲2,937,556.66美元。計劃中的出售是2023年11月1日通過的交易計劃的一部分。
根據最近的一份文件，艾伯維公司高管佩裏·西亞蒂亞斯定於2024年2月29日出售該公司的9,911股普通股。這些股票的總市值爲1,756,912.07美元，於2024年2月28日作爲績效股票直接從發行人手中收購。該交易遵循了西亞蒂亞斯在過去三個月中的近期銷售記錄，共計16,672股股票，總收益爲2,937,556.66美元。計劃中的出售是2023年11月1日通過的交易計劃的一部分。
有用
沒用
該公告為獨立文件：